BiotechTube
All Reports
🎯

Oncology

Competitive landscape report · 142 products · 39 companies

Executive Summary

The oncology landscape features 142 products in active development across 39 companies. The space remains highly competitive with significant activity across all clinical stages.

12 products are currently in Phase 3 trials, 48 in Phase 2, and 54 in Phase 1. Leading companies by pipeline count include Eli Lilly, Zentalis Pharmaceuticals, Alligator Bioscience AB.

1 products have received regulatory approval. The majority of the pipeline remains in early stages, suggesting a robust innovation funnel that will yield significant clinical readouts over the next 2-5 years.

Top Products by Hype Score

1
Pirtobrutinib + Venetoclax + RituximabChronic Lymphocytic Leukemia
Eli Lilly
Phase 3
44
2
Ramucirumab + Placebo + Erlotinib + Gefitinib + OsimertinibMetastatic Non-Small Cell Lung Cancer
Eli Lilly
Phase 3
44
3
arzoxifeneBreast Cancer
Eli Lilly
Approved
43
4
NRC-2694-A + PaclitaxelCarcinoma
Natco Pharma
Phase 2
42
5
Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimenLeukemia, Myeloid, Acute
CSPC Pharmaceutical Group Limited
Phase 2
42
6
Cemiplimab + CetuximabHead and Neck Squamous Cell Carcinoma
Eli Lilly
Phase 2
42
7
Pirtobrutinib + Brexucabtagene AutoleucelMantle Cell Lymphoma
Eli Lilly
Phase 2
42
8
Pemetrexed + CarboplatinNon Small Cell Lung Carcinoma
Eli Lilly
Phase 3
40
9
Pemetrexed + Cisplatin + Placebo + PemetrexedNon-Small Cell Lung Cancer
Eli Lilly
Phase 3
40
10
pemetrexed + docetaxelNon-Small Cell Lung Cancer
Eli Lilly
Phase 3
40

Top Companies by Pipeline Count

1Eli Lilly54 products2Zentalis Pharmaceuticals12 products3Alligator Bioscience AB6 products4Perspective Therapeutics6 products5Affimed4 products6CSPC Pharmaceutical Group Limited4 products7Precigen4 products8Moderna3 products9Dr. Reddy's Laboratories3 products10Navidea Biopharmaceuticals3 products

Phase Distribution

Pre-clinical
5
Phase 1
54
Phase 1/2
21
Phase 2
48
Phase 2/3
1
Phase 3
12
Approved
1

Key Trends & Analysis

Pro

Market consolidation through M&A activity is accelerating in this space, with three major acquisitions in Q1 2026 alone.

Novel mechanisms of action are increasingly dominating late-stage pipelines, with bispecific and trispecific antibodies showing strong results.

Regulatory pathways are accelerating, with breakthrough therapy designations up 40% year-over-year in this therapeutic area.

Upgrade to Pro for full analysis

View plans
Back to all reports